cd-18

Dexamethasone is a glucocorticoid receptor agonist and IL receptor modulator with anti-inflammatory, immunosuppressive, and apoptosis-inducing activities. It inhibits the production of inflammatory miRNA-155 exosomes in macrophages, significantly reduces inflammatory cytokine expression in neutrophils and monocytes, suppresses LPS-induced macrophage inflammation, and induces autophagy. It is commonly used to induce animal models of depression, muscle atrophy, and hypertension, and holds potential in COVID-19 research.

J-113863 is also a potent antagonist of the human CCR3 (IC50 of 0.58 nM) , but a weak antagonist of the mouse CCR3 (IC50 of 460 nM). J-113863 is inactive against CCR2, CCR4 and CCR5, as well as the LTB4 or TNF-α receptors. Anti-inflammatory effect. J-113863 is a potent and selective CCR1 (CD18) antagonist with IC50 values of 0.9 nM and 5.8 nM for human and mouse CCR1 receptors, respectively.

Leukadherin-1 is an allosteric activator of CD11b/CD18. Increasing CD11b/CD18-dependent cell adhesion to fibrinogen, Decreasing leukocyte motility and transendothelial migration; reduces inflammation.

Anti-Mouse CD18 Antibody (M18/2) is a rat-derived IgG2a, κ antibody inhibitor that targets mouse CD18.

Anti-CXCR4/CD184 Antibody represents a highly specialized monoclonal antibody specifically engineered to target the human C-X-C chemokine receptor type 4 (CXCR4) with exceptional binding affinity. It effectively facilitates the measurable blockade of the CXCL12/CXCR4 signaling axis across various preclinical experimental models to evaluate the modulation of cellular chemotaxis, hematopoietic stem cell mobilization, and the inhibition of tumor metastasis during strictly monitored laboratory observation periods and functional cell migration assays.

Anti-CXCR3/GPR9/CD183 Antibody is a potent monoclonal antibody targeting the chemokine receptor CXCR3, acting by competitively blocking the binding of pro-inflammatory chemokines (such as CXCL10) to the receptor's extracellular domain. The compound is an essential tool for investigating effector T cell recruitment, the pathogenesis of autoimmune diseases, and tumor immune microenvironment remodeling, aiming to inhibit excessive inflammatory cell infiltration by intervening in the CXCR3-mediated signaling axis.

Ulocuplumab-MMAE , an Anti-CXCR4/CD184 Reference Antibody, is produced in CHO cells. This antibody features a human IgG1 (huIgG1) heavy chain and a human kappa (hukappa) light chain. Its molecular weight is predicted to be 145.78 kDa.

The Anti-Mouse CXCR3/CD183 Antibody (CXCR3-173) is an IgG antibody inhibitor derived from a hamster originating from the United States, specifically targeting mouse CXCR3/CD183.

Anti-CD185/CXCR5 Antibody is a specialized monoclonal antibody target the C-X-C chemokine receptor type 5 protein, inhibition of ligand-induced intracellular signaling and cellular chemotaxis across various preclinical experimental models to modulate immune cell infiltration and tumor progression.

4F-Docetaxel (4FDT) is a fluorinated derivative of docetaxel that exhibits significant antitumor activity against hepatocellular carcinoma (HCC) and is suitable for research on liver cancer.

JAK1-IN-18 (Example 2) is a selective JAK1 inhibitor with an IC50 value of 0.15 nM, demonstrating significantly greater inhibitory potency for JAK1 compared to JAK2 and JAK3. It significantly reduces inflammation in ulcerative colitis (UC) mouse models induced by DSS and Crohn's disease (CD) rat models induced by DNBS. JAK1-IN-18 is applicable for research into autoimmune diseases (such as inflammatory bowel disease), viral infections (such as hepatitis B virus infection), and cancers (such as hematologic malignancies).